Compare PCRX & RYZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | RYZ |
|---|---|---|
| Founded | 2006 | 1842 |
| Country | United States | United States |
| Employees | N/A | 4300 |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2010 | 2014 |
| Metric | PCRX | RYZ |
|---|---|---|
| Price | $22.77 | $25.34 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 1 |
| Target Price | ★ $30.25 | N/A |
| AVG Volume (30 Days) | ★ 515.7K | 308.5K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 2.82% |
| EPS Growth | ★ 107.44 | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $541,533,000.00 | N/A |
| Revenue This Year | $6.78 | $75.79 |
| Revenue Next Year | $8.54 | $2.17 |
| P/E Ratio | $336.79 | ★ N/A |
| Revenue Growth | ★ 26.04 | N/A |
| 52 Week Low | $18.80 | $19.34 |
| 52 Week High | $27.64 | $29.03 |
| Indicator | PCRX | RYZ |
|---|---|---|
| Relative Strength Index (RSI) | 41.55 | 47.52 |
| Support Level | $22.13 | $23.77 |
| Resistance Level | $24.20 | $29.03 |
| Average True Range (ATR) | 1.26 | 1.44 |
| MACD | -0.25 | -0.27 |
| Stochastic Oscillator | 8.81 | 28.24 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Ryerson Holding Corp provides a metals service center, and value-added processor and is a distributor of industrial metals with operations in the United States, Canada, and Mexico. In addition to its North American operations, it conducts processing and distribution operations in China. It carries a full line of products in stainless steel, aluminum, carbon steel, and alloy steels and a limited line of nickel and red metals in various shapes and forms. The company has one operating and reportable segment, metals service centers. It derives substantially all of its sales from the processing and distribution of met. Geographically, the majority revenue is generated from the United States.